Treatment of HR+/HER2- breast cancer in urban mainland China: results from the CancerMPact Survey 2019.

Bhavna Murali Laura L DurbinSapna VijaykumarLinda YangSong LiLinda ZhaoStephanie HawthorneGena KanasChristine DavisOtávio Clark

Published in: Breast cancer research and treatment (2022)

HR+/HER2(-) breast cancer patients in urban mainland China were prescribed chemotherapy regimens more frequently than CDK4/6 inhibitors. Treatment practices varied, with physicians reporting the use of multiple modalities and treatment regimens for their patients.

Keyphrases

primary care
healthcare
end stage renal disease
ejection fraction
peritoneal dialysis
radiation therapy
young adults
cell proliferation
combination therapy
cell cycle
cross sectional
locally advanced
rectal cancer